Baqsimi ® (glucagon) nasal powder


This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How to identify BAQSIMI™ (glucagon) nasal powder overdose?

If overdosage occurs with Baqsimi (glucagon) nasal powder, the patient may experience gastrointestinal or cardiac effects, and serum potassium levels should be monitored.



If overdose occurs with Baqsimi, the patient may experience

  • nausea
  • vomiting
  • inhibition of gastrointestinal tract motility
  • increase in blood pressure, and
  • increase in pulse rate.1

In case of suspected overdose, serum potassium levels

  • may decrease
  • should be monitored, and
  • should be corrected if needed.1

If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.1


1Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

Date of Last Review: December 02, 2021

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon – Friday, 9am-7pm (EST), excluding holidays

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical